Abbott
-
CES 2023
Abbott Receives Three CES 2023 Innovation Awards for Advancements in Health Technology
Abbott (NYSE: ABT) has been recognized by the Consumer Technology Association (CTA) with three CES 2023 Innovation Awards for its life-changing technologies that are advancing the health tech industry and improving the lives of people worldwide. The CTA is the organization behind the Consumer Electronics Show (CES), the most influential technology event in the world. Abbott Logo (PRNewsFoto/Abbott) Ahead of…
Read More » -
Press Releases
Abbott’s FreeStyle® Libre 2 iOS App Cleared in U.S., Providing a Seamless Digital Experience to Simplify Diabetes Management
Abbott announced today that the U.S. Food and Drug Administration (FDA) has cleared the FreeStyle® Libre 2 iOS application for use with compatible iPhones1, providing a comprehensive digital offering for its FreeStyle Libre 2 integrated continuous glucose monitoring (iCGM) system. Providing breakthrough technology that is accessible and affordable4, the FreeStyle Libre portfolio is the number one continuous glucose monitoring (CGM) system worldwide5 and…
Read More »